Aktuella utlysningar, vecka 36, 2022
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Forskningsanslag – Svensk Lungmedicinsk Förening
Svensk Lungmedicinsk Förening (SLMF) inbjuder ansökningar om lungmedicinska forskningsanslag. SLMF stödjer forskning inom klinisk lungmedicin och syftar till att stimulera genomförandet av angelägna forskningsprojekt i Sverige. Det totala anslaget är inte bestämt vid utlysningen men brukar uppgå till 500 000 SEK. Anslaget fördelas på en eller två sökanden.
Closing date: September 30, 2022
Svensk Lungmedicinsk Förening | Utlysning av SLMFs Lungmedicinska forskningsanslag 2022
Urgent grants for the protection of data or research material – Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS)
Urgent call for proposals aiming to preserve data or research material. This enables researchers to ensure that certain research data or research material is made available for the future. The research data sought for may be measurement data and collected samples, interviews and participating observations. Projects may be in all scientific disciplines, including the humanities, natural sciences, social sciences and technology, as well as for interdisciplinary approaches.
Closing date: Applications may be submitted at any time except for the month of December.
Stipendier – Apotekarsocieteten
Apotekarsocieteten utlyser stipendier för forskning och vetenskap. Ändamålet är att främja vetenskapliga studier och forskning som täcker olika typer av farmaceutisk forskning från tidig läkemedelsutveckling till läkemedelsanvändning. Stipendier utlyses från följande stiftelser:
- Elisabeth och Alfred Ahlqvist stiftelse
- Apotekare Gunnar Hyltén stiftelse (stödjer läkemedelsforskning, företrädesvis inom området hjärt- och kärlsjukdomar)
- Apotekarsocietetens stipendiestiftelse för vetenskaplig forskning
- Apotekare CD Carlsson stiftelse
- Göran Schills (enbart post doc)
Closing date: October 31, 2022
Forskning och vetenskap - Apotekarsocieteten
The Rolf Luft Grant for Instrumentation” is now open for applications
With this call SRP Diabetes wishes to support the most excellent younger Principal Investigators (consolidator level) at Karolinska Institutet to obtain critical instrumentation for their research. Grants for instruments in the range of 200 000 SEK up to 4 MSEK can be applied for.
Please see attached call text for information on conditions and how to apply and the attached application template.
Closing date: October 1, 2022
Accelerating diagnosis and treatment -- Versus Arthritis, GB
This call for applications for research funding focusses on two of the priority areas:
- Early detection and prevention: spotting the biological signatures of arthritis early to maximise the opportunities for timely intervention and preventing it from getting worse.
- Targeted treatments: taking the guesswork out of treatment by increasing effective, reliable and timely drug and non-drug solutions to reduce, manage or cure disease.
The impacts sought from this investment are progress toward:
- better understanding and tools to identify markers of risk to enable proactive screening and early detection (secondary prevention) approaches
- better tools and biomarkers to diagnose arthritis accurately and as rapidly as possible after symptoms begin
- clinical and care pathways applying a precision medicine and holistic approach – accounting for individual variability in genes, environment and lifestyle and the management of pain, mental health and fatigue
- more effective, safer treatments and ultimately cures, that work for more people
- better tools to help decide the most appropriate treatments
- better understanding of how different diseases can be most effectively tackled together.
The lead applicant must be based at an eligible UK institution.
Awards of up to 60 months duration, between £50,000-£800,000 in value, are available.
Closing date: 9th November 2022
Mental health award – integrating sleep and circadian science into our understanding and treatment of anxiety, depression and psychosis --Wellcome, GB
This supports teams researching the interdependent roles of sleep and circadian rhythm disruptions in the development and resolution of anxiety, depression, or psychosis.
Teams may be based anywhere in the world apart from mainland China and sanctioned territories. Wellcome encourages applications from multidisciplinary teams, including those outside the life sciences. All applications must include the involvement of people with lived experience in the planning, design and delivery of the research.
Funding is worth up to £3 million for up to five years.
Closing date 19 October 2022
Research fellowship -- United European Gastroenterology, EUR
This enables a researcher to spend 12 months working with a renowned European principal investigator on an extensive research project. Candidates may carry out research they cannot do in their home institution and build their network and learn new research skills.
Applicants must be clinical or basic researchers specialised in digestive diseases, have completed their PhD no longer than three years ago or be in gastroenterology, hepatology or surgery training or have completed it within the last three years, have significant research experience and reside in Europe or the Mediterranean area. Candidates must approach a principal investigator who will host them. The hosting PI must be based in Europe or the Mediterranean area and must not be based in the fellow’s country of residence.
The fellowship is worth €50,000 for one year.
Closing date 22 October 2022 (Forecast; we have no information from the funder yet about the next call. Based on past experience, we forecast the deadline to be around October 2022.) This call is repeated 2 times a year.
Biomedical research project grants -- Motor Neurone Disease Association, GB
These support research aimed at understanding the causes of motor neurone disease, elucidating disease mechanisms, and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Grants support single pieces of work designed to answer a single question or a small group of related questions.
Applicants can be based outside the UK and the Republic of Ireland provided the project is unique in concept or design, namely no similar research is being performed in the UK, and involves an aspect of collaboration with a UK institute.
Funding is worth up to £95,000 per year for non-London institutes and up to £100,000 per year for London institutes for up to three years.
Closing date 28 October 2022
CRACK IT challenges - single phase competition -- National Centre for the Replacement, Refinement and Reduction of Animals in Research, GB
This aims to develop quantitative structure-activity relationship (QSAR) and molecular docking tools that reliably predict thyroid receptor-mediated human endocrine disruption.
Any UK or EU body, public or private, may apply. Applications can be from single organisations, investigators or from consortia. The lead applicant must be from the UK or EU.
One award, worth up to £100,000 for up to one year, is available.
Closing date 3 November 2022
Federal Funding agencies
Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional): NIH
The National Institute on Drug Abuse (NIDA) seeks research for the discovery and development of medications to prevent and treat opioid use disorder (OUD) and/or psychostimulant (cocaine or methamphetamine) use disorder (PsUD) and overdose.
Closing date: Applications will be accepted on a rolling basis, beginning on September 3, 2022 until September 02, 2025.
Funding Opportunity Announcement (FOA): PAR-22-200.
Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required): NIH
The purpose of this funding opportunity announcement (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.
Closing date: February 28, 2023 and October 26, 2023. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-DK-22-020
BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits (UM1 Clinical Trial Not Allowed): NIH
This funding opportunity announcement (FOA) is intended to support the creation of Centers for accelerated engineering and optimization of high-impact, molecular technologies to monitor and/or manipulate brain cell activity in experimental animals. The Centers will produce high-impact molecular probes such as, but not limited to, fluorescent protein indicators of neuronal state variables (e.g., intracellular calcium, membrane voltage, released neurotransmitters/neuromodulators, etc.), molecular integrators of neural activity, optogenetic, chemogenetic, sonogenetic, magnetogenetic actuators, and activity-dependent molecular switches. This FOA is part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN Initiative Armamentarium project, whose goal is to generate tools to specifically access, manipulate, and monitor brain cell types across multiple species. In this FOA, technology optimization is sought for existing tools for brain cell monitoring or manipulation that are beyond the proof-of-concept stage and that can be delivered selectively as payloads to cell types using newly developed brain cell access reagents.
Closing date: June 28, 2023; February 15, 2024; October 17, 2024. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-MH-22-245
Inflammatory bowel diseases therapeutics incubator – request for proposals, Crohn’s and Colitis Foundation of America, US
The Crohn’s and Colitis Foundation of America invites proposals for its inflammatory bowel diseases therapeutics incubator. This supports research to create new therapeutic product opportunities derived from breakthrough academic research that has identified novel and differentiated drug targets for the treatment of Crohn’s disease and ulcerative colitis. Candidate drug targets should meet most if not all the following criteria:
•addressing an unmet need in IBD; linked to human IBD; novel and differentiated mechanism of action; validated; druggable; available screening assays; available tool compounds or antibodies; available biomarkers; favourable safety profile.
Applications may be submitted by a team with one lead lead PI and at least one co-PI. The PI must be a senior faculty member with relevant expertise in IBD biology and therapeutic target discovery. Co-PIs must be academic researcher with relevant expertise who is at any level of the academic professional track. PIs and co-PIs must be employed by a non-profit research institution. International applicants are eligible. Applications are strongly encouraged from diverse teams of applicants that include women, underrepresented racial and ethnic groups, individuals with disabilities or individuals from disadvantaged backgrounds.
Funding is worth up to USD 1.5 million per project over a three-year period.
Closing date: October 3, 2022.
Improving methods for conducting patient-centred outcomes research, Patient-Centered Outcomes Research Institute (PCORI), US
With this PCORI Funding Announcement (PFA), PCORI aims to fund studies that address high-priority methodological gaps in patient-centered outcomes research (PCOR) and clinical comparative effectiveness research (CER).
PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/CER studies.
For the 2022 Methods PFA, PCORI has identified the following areas as programmatic priorities:
- Methods to Improve the Use of Artificial Intelligence (AI) and Machine Learning (ML) in Clinical Research
- Methods to Improve Study Design
- Methods to Support Data Research Networks
- Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER
Funds Available Up To$12 million for three years.
Closing date: October 4, 2022; 5:00 pm ET (LOI); January 10, 2023; 5:00 pm ET (Full proposal).
Healthy Aging: Optimizing Physical and Mental Functioning Across the Aging Continuum, Patient-Centered Outcomes Research Institute (PCORI), US
The Healthy Aging Targeted PCORI Funding Announcement will solicit applications for CER studies that focus on different phases of the aging continuum and aim to achieve one or more of the following four goals:
- maintaining function and independence
- facilitating chronic disease management
- supporting individuals with significant functional impairment
- reducing caregiving burden and improving quality of life
Funds Available Up To $25 million for five years.
Closing date: October 4, 2022; 5:00 pm ET (LOI); January 10, 2023; 5:00 pm ET (Full proposal).
Pioneer spinocerebellar ataxias type 3 translational research awards, National Ataxia Foundation (NAF), US
The National Ataxia Foundation invites letters of intent for its pioneer spinocerebellar ataxias type 3 translational research awards. These support research on the development of treatments or improvements to patient care for spinocerebellar ataxias type 3. Proposals may incorporate other forms of ataxia but must have a predominant focus on SCA3 translational or clinical research.
One grant, worth USD 100,000 for one year, is available.
Closing date: October 5, 2022 by 12 AM Central Time (LOI); November 23, 2022 by 12 AM Central Time (Full proposal).
Team science award, Melanoma Research Alliance (MRA), US
The Melanoma Research Alliance joint with the Rising Tide Foundation for Clinical Cancer Research invite applications for its team science award. This supports novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term.
All research groups with a track record in melanoma are eligible to apply. Applicants should actively involve patients in the protocol design.
Up to two awards worth up to USD 1,500,000 over a maximum of five years will be supported.
Closing date: 11:59 p.m. Eastern Time, October 5, 2022 (LOI); 11:59 p.m. Eastern Time, January 18, 2023 (Invited Full proposal).